ImpediMed Limited (ASX:IPD)
Australia flag Australia · Delayed Price · Currency is AUD
0.0160
-0.0010 (-5.88%)
At close: Mar 6, 2026

ImpediMed Company Description

ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally.

The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-care body composition analysis; and HF-Dex analysis for point-of-care heart failure fluid assessment.

It also provides SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications.

ImpediMed Limited was incorporated in 1999 and is headquartered in Carlsbad, California with additional office in Lindfield, Australia.

ImpediMed Limited
ImpediMed logo
Country Australia
Founded 1999
Industry Medical Devices
Sector Healthcare
Employees 77
CEO Parmjot Bains

Contact Details

Address:
5900 Pasteur Court
Carlsbad, California 92008
United States
Phone 760 585 2100
Website impedimed.com

Stock Details

Ticker Symbol IPD
Exchange Australian Securities Exchange
Fiscal Year July - June
Reporting Currency AUD
ISIN Number AU000000IPD8
SIC Code 3845

Key Executives

Name Position
Dr. Parmjot Bains M.D. MD, Chief Executive Officer and Director
McGregor Grant BEc, C.A., FCIS, GAICD Chief Financial Officer and Executive Director